---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-385886"
form_type: "8-K"
ticker: "TYRA"
cik: "0001863127"
company_name: "Tyra Biosciences, Inc."
filed_at: "2026-09-09T11:10:06+00:00"
generated_at: "2026-09-09T11:15:18.929003+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Tyra reports positive SURF302 data: 79% ORR, 57% CR at 60mg in FGFR3-altered NMIBC

## Summary
- SURF302: 60mg QD ORR 79% (11/14), CR 57% (8/14) at 3 months; 50mg ORR 67%, CR 33%.
- Safety: no Grade 4/5 TEAEs; Grade 3 treatment-related AEs in 4.5% (2/44), none at 60mg; no dose reductions at 60mg.
- Exposure-response: ORR 86% above AUC 2500 vs 58% below; supports 60mg adjuvant, 70mg cohort planned for ablative.
- Plans: complete 60mg enrollment, initiate 70mg cohort, engage health authorities; registrational adjuvant study expected 2027.
- Also: SURF303 first patient CR at 3 months; BEACH301 cleared fifth dose level in achondroplasia.

## SEC filing metadata
- accession: 0001193125-26-385886
- form_type: 8-K
- ticker: TYRA
- cik: 0001863127
- company_name: Tyra Biosciences, Inc.
- filed_at: 2026-09-09T11:10:06+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1863127/000119312526385886/0001193125-26-385886-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1863127/000119312526385886/d167841d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-385886
- JSON: https://secwatch.observer/filing/0001193125-26-385886.json
- Plain text: https://secwatch.observer/filing/0001193125-26-385886.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.